Elsevier

Kidney International

Volume 101, Issue 5, May 2022, Pages 1073-1076
Kidney International

Research Letter
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients

https://doi.org/10.1016/j.kint.2022.02.011Get rights and content

Section snippets

Results

Sixty-seven kidney transplant recipients (median age 56.6 years; interquartile range [IQR] 47–64.6 years; n = 41 [61.2%] men) showed a weak humoral response after 3 doses of the mRNA-1273 vaccine and received a fourth dose (Supplementary Methods). None of these patients had a history of COVID-19 and displayed anti–nucleocapsid antibodies. The median interval from transplantation to the fourth dose was 6.1 years (IQR 2.2–11.4 years). As for immunosuppressive therapy, 97% of the study patients

Discussion

In this cohort of 67 kidney transplant recipients who showed a low immune response after 3 doses of the mRNA-1273 (Moderna) vaccine, a fourth dose significantly increased the neutralizing response against the Delta variant. Specifically, the proportion of patients harboring neutralizing antibodies against the Delta strain rose significantly from 16% to 66%. In our study, men displayed higher neutralizing ID50 titers than did women. Although this observation has no obvious pathophysiological

Disclosure

All the authors declared no competing interests.

First page preview

First page preview
Click to open first page preview

References (9)

There are more references available in the full text version of this article.

Cited by (0)

View full text